BMS and Celgene receive ‘second request’ from US FTC
MLex Summary: Bristol-Myers Squibb and Celgene have each received a “second request” for additional information from Federal Trade Commission officials reviewing their merger. The drugmakers understand that the FTC review focuses...To view the full article, register now.
Already a subscriber? Click here to view full article